GlassScriptPhysician profile
Ko G Liuo
NPI 1841683406
$3,534.85
in general payments reported to CMS, 2019-2025
20 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $776 · 2022: $475 · 2023: $457 · 2024: $563 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,283.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $691.28 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $651.16 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $330.48 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $284.97 | 2024-2025 | Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $259.29 | 2021-2025 | Trintellix |
| Alkermes, INC. | $233.43 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $221.31 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $162.77 | 2021-2025 | Fanapt |
| Axsome Therapeutics, INC. | $142.27 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $92.99 | 2023-2025 | Spravato |
| Lundbeck LLC | $89.24 | 2021-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $70.09 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $66.25 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $54.40 | 2021 | |
| Bausch Health US, LLC | $45.17 | 2021-2024 | Aplenzin |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $44.74 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $35.65 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.61 | 2025 | |
| Ironshore Pharmaceuticals INC. | $21.00 | 2022 | |
| Acadia Pharmaceuticals INC | $15.75 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ko Liuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.